Brief: CSPC Pharmaceutical Enters Into Exclusive License Agreement For SYH2086 With Madrigal
July 30 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK: ENTERING INTO EXCLUSIVE LICENSE AGREEMENT FOR SYH2086 WITH MADRIGAL ELIGIBLE FOR UP TO $2.075 BILLION IN PAYMENTS DEAL FOR GLOBAL DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SYH2086 Further company coverage: 1093.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)